Real-time nucleic acid amplification-based qualitative assay for specific genotyping of E6/E7 mRNA from HPV 16, 18, 31, 33, 45, 52, and 58.
A useful tool to identify women at risk for Cervical Cancer.
1 “HPV E6/E7 mRNA test for the detection of high-grade cervical intraepithelial neoplasia”
PreTect HPV-Proofer 7® is based on NASBA technology, an enzymatic amplification process that can amplify and detect RNA even in the presence of DNA. Unlike PCR, an amplification run is performed under isothermal conditions at 41°C, achieving a fast result.
PreTect HPV-Proofer 7® is the assay with the highest specificity and positive predictive value on the market today 1. This means that PreTect HPV-Proofer 7® can reduce the cost of follow-up – and the number of women requiring referrals and additional tests – by more than 70%.
1 Derbie A, Mekonnen D, Woldeamanuel Y, Van Ostade X, Abebe T. (2020). “HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review”.
PreTect HPV-Proofer 7® identifies the 7 most common genotypes related to Cervical Cancer causing more than 90% of all cases of Cervical Cancer in the world. Therefore, there is only a very small chance of developing Cervical Cancer caused by one of the other 7 uncommon HR-HPV genotypes.
PreTect HPV-Proofer 7® is clinically validated according to the EU IVD regulations.
We develop medical devices and safe, state-of-the-art molecular technologies that empower you to take control of your health through prevention.
Have Questions? Our team is happy to answer any questions you may have.